This company is no longer active
Athenex (2MT0) Stock Overview
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
2MT0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Athenex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.27 |
| 52 Week High | US$22.77 |
| 52 Week Low | US$1.43 |
| Beta | 1.35 |
| 1 Month Change | 0% |
| 3 Month Change | -3.31% |
| 1 Year Change | -65.09% |
| 3 Year Change | -98.24% |
| 5 Year Change | -98.85% |
| Change since IPO | -98.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2MT0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | -1.3% |
| 1Y | -65.1% | -7.9% | 7.7% |
Return vs Industry: 2MT0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 2MT0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2MT0 volatility | |
|---|---|
| 2MT0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2MT0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2MT0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 275 | Johnson Lau | www.athenex.com |
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company’s Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
Athenex, Inc. Fundamentals Summary
| 2MT0 fundamental statistics | |
|---|---|
| Market cap | €9.10m |
| Earnings (TTM) | -€90.28m |
| Revenue (TTM) | €94.74m |
Is 2MT0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2MT0 income statement (TTM) | |
|---|---|
| Revenue | US$102.82m |
| Cost of Revenue | US$76.12m |
| Gross Profit | US$26.70m |
| Other Expenses | US$124.68m |
| Earnings | -US$97.98m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.31 |
| Gross Margin | 25.97% |
| Net Profit Margin | -95.29% |
| Debt/Equity Ratio | -511.7% |
How did 2MT0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/14 13:16 |
| End of Day Share Price | 2023/02/14 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Athenex, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Hu | Deutsche Bank |
| Umer Raffat | Evercore ISI |
| Jialin Zhang | ICBC International Research |